MedLife (M) Q1 2026 earnings summary

Executive summary

• Consolidated pro forma turnover reached up to RON 856.2 million in Q1 2026, up as much as 10.1% year-over-year, with organic growth of 9%.

• Clinics were the main growth driver, with hospitals and laboratories also performing strongly due to investments in advanced equipment and expanded services.

• Strategic expansion included opening a new clinic in Arad and finalizing the Medstar acquisition, consolidated from February.

• Continued investments in robotics, genomics, digitalization, and corporate healthcare products supported operational growth and market share gains.

• The Longevity 100 Plus genomics project delivered its first results, advancing personalized and preventive medicine.

Financial highlights

• Pro forma EBITDA rose up to 10% to RON 124.3 million, with a margin of 16% (pro forma) and 14% (IFRS).

• Pro forma net result was RON 12.6 million, a 90% increase year-over-year in some reports, while other reports show an 18.9% increase.

• Operating profit ranged from RON 42.5 million (down 3.3% YoY) to RON 47 million (up 7% YoY), depending on reporting basis.

• Net cash from operating activities decreased by over 22% year-over-year, mainly due to timing and working capital changes.

• CapEx budget for 2026 is EUR 20 million, excluding acquisitions.

Outlook and guidance

• Expectation of continued solid demand and healthy growth, supported by organic development and new facilities.

• Margin improvement anticipated progressively through the year to reach the 14.5% full-year EBITDA margin target.

• Strategic focus remains on genetics, personalized medicine, digitalization, and operational efficiency.

• No further price increases or major acquisitions planned for the remainder of the year, but selective M&A opportunities will be evaluated.

• CAPEX guidance for 2026 is EUR 20 million, excluding acquisitions.